Shamburg News · 8-K filed Nov 13, 2026, 8:00 AM EST
Immunic Reports Third Quarter 2026 Results; Phase 3 ENSURE Data Expected December 2026
IMUX · IMMUNIC, INC.
- Earnings
- Leadership change
- Other event
- Materiality: high
Immunic, Inc. reported a net loss of approximately $42.3 million, or $0.99 per basic and diluted share, for the quarter ended September 30, 2026, compared with $1.32 per share a year earlier. Total operating expenses were $43.4 million for the quarter, and cash and cash equivalents were $132.0 million as of September 30, 2026, which the company expects to fund operations into late 2027. The company stated that top-line data from its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis are expected in December 2026, and it appointed Jaa Roberson as Chief People Officer and Chitrang Davé as Chief Data and Digital Officer.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001493152-26-051543.
Written from the filing by Shamburg Markets. Figures are as reported by the company.